Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
EXTON, Pa. - ViroPharma Inc. on Wednesday released new data on the effectiveness of its drug Cinryze against a hereditary disorder that causes dangerous swelling.
| VPHM | 13.66 |  -0.26 |
ViroPharma plans to begin marketing Cinryze next month to treat hereditary angioedema, a protein deficiency that causes rapid swelling of the hands, feet and face.
The company said a study of 88 patients with the disease showed their symptoms improved within a median of 30 minutes after receiving treatment with Cinryze.
ViroPharma said 93 percent of patients reported improved symptoms within four hours of taking the drug. None of the patients in the study who experienced larynx problems required hospitalization, the company reported.
The results were reported at the American College of Allergy, Asthma and Immunology's annual meeting in Seattle.
Shares of ViroPharma Inc. fell 29 cents, or 2.6 percent, to close at $11.03.
You've heard the talk of "Green" throughout the whole of 2008, bu...
Lenovo, with its IdeaPad line series is previewing Y-Series IdeaPad Y650 laptops at CES in Las Vegas together with other new Ideapad Y-series.
After break of the psychological resistance 1.5100, yesterday the Pound/Dollar made a significant rise, reaching a peak at 1.5279. But further bu...
Cisco will unveil new consumer products and initiatives during apress conference at the 2009 ...
Get your next web design project done with our los angeles web design team - Best web design with great price.
Buy Real Estate, Tax Liens, and more- Fund your business or franchise without debt
Building your business and corporate credit for your small business.
Partners   
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
